TGFβR2KO IL13Rα2 CAR T-Cells

TGFβR2 knockout IL-13 receptor alpha-2 CAR T-cell · City of Hope Medical Center

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TGFβR2KO IL13Rα2 CAR T-Cells, covering 2025-06-26 to 2025-06-26. Get the full timeline:

Most recent: Clinical Trial Update: Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma [Phase 1]

See pricing